Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review

Clinical and Translational Oncology

Volumn 13, Issue 2, 2011, Pages 121-132

  García Sáenz, José A ^a   Custodio, Ana ^a   Casado, Antonio ^a   Vidart, José Antonio ^a   Coronado, Pluvio J ^a   Martín, Miguel ^a   López Tarruella, Sara ^a   Puente, Javier ^a   Fernández, Cristina ^a   Díaz Rubio, Eduardo ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Adjuvant chemotherapy; Early stages; Ovarian cancer; Platinum based therapy; Taxanes

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEARING LOSS; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; CANCER CENTER; DISEASE COURSE; EVALUATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; OVARIECTOMY; OVARY TUMOR; PATHOLOGY; REVIEW; RISK FACTOR; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER CARE FACILITIES; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARIECTOMY; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 79958055229     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0629-6     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics 2009. CA Cancer J Clin 59:225-249
2. Benedet JL, Bender H, Jones H 3rd et al (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70:209-262
3. Heintz AP, Odicino F, Maisonneuve P et al (2001) Carcinoma of the ovary. J Epidemiol Biostat 6:107-138 (Pubitemid 33134081)
4. Ozols RF, Rubin SC, Thomas GM et al (2000) Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC (eds) Principles and practice of gynecologic oncology, 3rd edn. Lippincott, Williams and Wilkins, Philadelphia, PA, pp 981-1058
5. Ahmed FY, Wiltshaw E, A'Hern RP et al (1996) Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 14:2968-2975 (Pubitemid 26371455)
6. Sonoda Y (2004) Management of early ovarian cancer. Oncology 18:343-356
7. Thigpen JT (1999) Limited-stage ovarian carcinoma. Semin Oncol 26:29-33
8. Zanetta G, Rota S, Chiari S et al (1998) The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. Ann Oncol 9:1097-1101 (Pubitemid 28518148)
9. Le T, Krepart GV, Lotocki RJ, Heywood MS (1999) Clinically apparent early stage invasive epithelial ovarian carcinoma: should all be treated similarly? Gynecol Oncol 74:252-254
10. Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248-1259 (Pubitemid 34177431)
11. Winter WE 3rd, Maxwell GL, Tian C et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:3621-3627 (Pubitemid 47372600)
12. Chi DS, Eisenhauer EL, Lang J et al (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559-564 (Pubitemid 44602167)
13. Eisenkop SM, Spirtos NM, Lin WC (2006) "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol 103:329-335
14. Winter WE III, Maxwell GL, Tian C et al (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 26:83-89
15. Eisenhauer EL, Abu-Rustum NR, Sonoda Y et al (2008) The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 108:276-281
16. Trimbos JB, Vergote I, Bolis G et al (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 95:113-125 (Pubitemid 36193260)
17. Colombo N, Guthrie D, Chiari S et al (2003) International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95:125-132 (Pubitemid 36193261)
18. Swart AC on behalf of ICON Collaborators (2007) Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). J Clin Oncol 25:276s (Abstr 5509)
19. Murray JF, Shanmugaratnam K, Ringertz N et al (2006) International histologic classification of tumors. A report by the Executive Committee of the International Council of Societies of Pathology. Cancer 33:1480-1483
20. Cardenes H, Randall ME (2000) Integrating radiation therapy in the curative management of ovarian cancer: current issues and future directions. Semin Radiat Oncol 10:61-70 (Pubitemid 30044150)
21. Redman CW, Mould J, Warwick J et al (1993) The West Midlands epithelial ovarian cancer adjuvant therapy trial. Clin Oncol (R Coll Radiol) 5:1-5 (Pubitemid 23069077)
22. Chiara S, Conte P, Franzone P et al (1994) High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. Am J Clin Oncol 17:72-76 (Pubitemid 24062739)
23. Vergote IB, Vergote-De Vos LN, Abeler VM et al (1992) Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 69:741-749
24. Bolis G, Colombo N, Pecorelli S et al (1995) Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate(32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 6:887-893
25. Young RC, Brady MF, Nieberg RK et al (2003) Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin: a Gynecologic Oncology Group study. J Clin Oncol 21:4350-4355 (Pubitemid 46621811)
26. Chi DS, Waltzman RJ, Barakat RR, Spriggs DR (1999) Primary intravenous paclitaxel and platinum chemotherapy for high-risk Stage I epithelial ovarian carcinoma. Eur J Gynaecol Oncol 20:277-280 (Pubitemid 30113727)
27. Raymond E, Drolet Y, Marpeu L et al (1997) Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 72:181-190 (Pubitemid 27244883)
28. Young RC, Walton LA, Ellenberg SS et al (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322:1021-1027 (Pubitemid 20146659)
29. Tropé C, Kaern J, Hogberg T et al (2000) Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 11:281-288 (Pubitemid 30214664)
30. Trimbos JB, Parmar M, Vergote I et al (2003) International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95:105-112 (Pubitemid 36196730)
31. Elit L, Chambers A, Fyles A et al (2004) Systematic review of adjuvant care for women with stage I ovarian carcinoma. Cancer 101:1926-1935
32. Winter-Roach BA, Kitchener HC, Dickinson HO (2009) Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev 21:CD004706
33. Hreshchyshyn MM, Park RC, Blessing JA et al (1980) The role of adjuvant therapy in stage I ovarian cancer. Am J Obstet Gynecol 138:139-145 (Pubitemid 10001207)
34. Krafft W, Morack G, Flach W et al (1980) [The therapy of the early ovarian cancer (T1/T2 M0N0) (author's transl)]. Arch Geschwulstforsch 50:664-671
35. Sigurdsson K, Johnsson JE, Trope C (1982) Carcinoma of the ovary, stages I and II. A prospective randomized study of the effects of postoperative chemotherapy and radiotherapy. Ann Chir Gynaecol 71:321-329
36. McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6 (Pubitemid 26012496)
37. Piccart MJ, Bertelsen K, Stuart G et al (2003) Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 13:144-148 (Pubitemid 38228756)
38. Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200 (Pubitemid 46606249)
39. Du Bois A, Lück HJ, Meier W et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1329
40. Greimel ER, Bjelic-Radisic V, Pfisterer J et al (2006) Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 24:579-586 (Pubitemid 46630419)
41. Bell J, Brady MF, Young RC et al (2006) Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 102:432-439 (Pubitemid 44353663)
42. Omura GA, Bundy BN, Berek JS et al (1989) Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 7:457-465 (Pubitemid 19098140)
43. Vergote I, De Brabander J, Fyles A et al (2001) Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357:176-182 (Pubitemid 32108089)
44. Helewa ME, Krepart GV, Lotocki R (1986) Staging laparotomy in early epithelial ovarian carcinoma. Am J Obstet Gynecol 154:282-286 (Pubitemid 16095403)
45. Young RC, Decker DG, Wharton JT et al (1983) Staging laparotomy in early ovarian cancer. JAMA 250:3072-3076 (Pubitemid 14201622)
46. Mayer AR, Chambers SK, Graves E et al (1992) Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol Oncol 47: 223-227
47. Skirnisdottir I, Sorbe B, Seidal T (2001) P53, bcl-2, and bax: their relationship and effect on prognosis in early-stage epithelial ovarian carcinoma. Int J Gynecol Cancer 11:147-158 (Pubitemid 32381664)
48. Skirnisdottir I, Sorbe B, Seidal T (2001) The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer 11:119-129 (Pubitemid 32381660)
49. Ogawa S, Kaku T, Kobayashi H et al (2002) Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett 176:111-118 (Pubitemid 34085076)
50. Denkert C, Kobel M, Pest S et al (2002) Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160:893-903 (Pubitemid 34224579)
51. Maihle NJ, Baron AT, Barrette BA et al (2002) EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res 107:247-258
52. Brustman H, Naude S (2002) Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and FIGO stage. Gynecol Oncol 84:47-52
53. Cannistra SA, Matulonis U, Penson R et al (2006) Bevacizumab in patients with advanced platinumresistant ovarian cancer. J Clin Oncol 24:18s (Abstr 5006)
54. Richardson DL, Backes FJ, Seamon LG et al (2008) Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol 111:461-466